CLAIMS:

1. The use of a Vanadium containing compound of the formula:

5 wherein L-L' is:

or

and L' is COO, CONR⁵, CONHR⁶, CH₂NR⁵R⁶

or wherein L and L' together form a group:

$$R^1$$
 R^2

15

or a group:

$$R^{1} \xrightarrow[R^{2}]{NH} \xrightarrow[N]{L'} N - R^{4}$$

wherein L" is O, S or NH;

R¹, R², R³, R⁴, R⁵ and R⁶ are independently H, hydroxyl, C₁₋₆ alkyl, optionally substituted by hydroxy or NR⁷R⁸, C₃₋₆ cycloalkyl, optionally substituted by hydroxy or NR⁷R⁸, phenyl, optionally substituted by C₁₋₃ alkyl, hydroxy, NR⁷R⁸ or SO₃, (OCH₂CH₂)_n (NHCH₂CH₂)_n, an amino acid or a peptide consisting of 2 to 5 amino acids; and

R⁷ and R⁸ are independently H or C₁₋₆ alkyl;

- or a pharmaceutically acceptable salt thereof
 in the manufacture of a medicament for use in inhibiting phosphatases.
 - 2. The use of a Vanadium containing compound of the formula:

15

wherein L-L' is:

or

and L' is COO, CONR5, CONHR6, CH2NR5R6

or wherein L and L' together form a group:

5

or a group:

10

15

wherein L" is O, S or NH;

 R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently H, hydroxyl, C_{1-6} alkyl, optionally substituted by hydroxy or NR^7R^8 , C_{3-6} cycloalkyl, optionally substituted by hydroxy or NR^7R^8 , phenyl, optionally substituted by C_{1-3} alkyl, hydroxy, NR^7R^8 or SO_3 , $(OCH_2CH_2)_n$ ($NHCH_2CH_2$)_n, an amino acid or a peptide consisting of 2 to 5 amino acids; and

R⁷ and R⁸ are independently H or C₁₋₆ alkyl; or a pharmaceutically acceptable salt thereof

20 in the manufacture of a medicament for use in inhibiting phosphatases.

10

15

20

25

- 3. The use as claimed in claim 1 or claim2 wherein the medicament is for use in inhibiting inositol phosphatases such as PTEN.
- 4. The use as claimed in any one of claims 1 to 3 wherein the medicament is for use in treating diseases where inhibition of apoptosis is required.
 - 5. The use as claimed in claim 4 wherein the disease or condition is a neurodegenerative disease such as Alzheimer's disease, wound healing, burns, heart hypertrophy, hypoxia, ischemia, diabetes, sports injuries and as an anticancer agent.
 - 6. The use as claimed in any one of claims 1 to 5 wherein the compound is potassium bisperoxo (bipyridine) oxovanadate (bpV(bipy), potassium bisperoxo(1,10-phenanthroline)oxovanadate (pV(phenanthroline)), potassium bisperoxo (piconlinate) oxovanadate (pV(pic)) and potassium bisperoxo(phenylbiguanide)oxovanadate (pV(biguan)).
 - 7. The use as claimed in any one of claims 1 to 5 wherein the compound is pV(phenbig) [dipotassium bisperoxo(phenylbiguanide)oxovanadate] or bpV(HOpic) [dipotassium bisperoxo(5-hydroxypyridine-2-carboxyl)oxovanadate].
 - 8. The use as claimed in claim 7 wherein the medicament is for the treatment of diabetes.
 - 9. A Vanadium containing compound of the formula:

where L-L' is:

or

and L' is CONR⁵ and CONHR⁶; and

- 5 wherein R^1 is C_{1-6} alkyl.
 - 10. A Vanadium containing compound of the formula:

10

where L-L' is:

or

15

and L' is CONR5 and CONHR6; and

wherein R¹ is C₁₋₆ alkyl.

11. A Vanadium containing compound of the formula:

5

15

20

wherein L and L' together form a group:

wherein L" is O, S or NH;

 R^1 , R^2 , R^3 and R^4 are independently H, C_{1-6} alkyl, optionally substituted by hydroxy or NR^7R^8 , C_{3-6} cycloalkyl, optionally substituted by hydroxy or NR^7R^8 , phenyl, optionally substituted by C_{1-3} alkyl, hydroxy, NR^7R^8 or SO_3 , $(OCH_2CH_2)_n$ ($NHCH_2CH_2$)_n, an amino acid or a peptide consisting of 2 to 5 amino acids; and R^7 and R^8 are independently H or C_{1-6} alkyl; or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical formulation comprising a compound as claimed in any one of claims 9 to 11, optionally together with one or more pharmaceutically acceptable excipients, diluents or carriers.